Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Thursday, February 19, 2026 2 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc (KNSA) will host a conference call on February 24, 2026, to discuss its financial results for the fourth quarter and full year 2025. The call will be accessible via a live webcast on the company's website. Participants can register to join the conference call by telephone, receiving a confirmation email with details. Kiniksa focuses on developing treatments for diseases with unmet needs, especially in the cardiovascular sector.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is set to report financial results, indicating ongoing operational activity.
The conference call presents an opportunity for investors to learn more about the company's portfolio.
Kiniksa's commitment to developing therapies for unmet medical needs highlights its innovative approach.
Full Press Release Details
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.